Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid Plaque Clear all
Completed Phase 2 Interventional

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

NCT01634087
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Itacitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hot Springs, Arkansas • Los Angeles, California • Clinton, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 26, 2026, 2:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

NCT00954915
View directory record Official record
Conditions
Psoriasis
Interventions
teplizumab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 2 Interventional

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

NCT00504270
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, RG3421 120mg, RG3421 20mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

NCT00990561
View directory record Official record
Conditions
Stable Plaque Psoriasis
Interventions
Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jun 26, 2026, 2:47 AM EDT
Active, not recruiting No phase listed Observational

AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management

NCT06376851
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Diagnostic Test
Lead sponsor
HeartFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339
View directory record Official record
Conditions
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jun 26, 2026, 2:47 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Determination of the Safety and Efficacy of a Novel Oral Rinse on Oral Health

NCT04197427
View directory record Official record
Conditions
Plaque, Gingivitis
Interventions
Experimental Oral Rinse, Placebo
Device
Lead sponsor
You First Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

NCT03073200
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Placebo, Etanercept
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Jun 26, 2026, 2:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jun 26, 2026, 2:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

South Asians and Coronary Plaque Registry

NCT05367297
View directory record Official record
Conditions
Coronary Artery Disease, Heart Diseases
Interventions
Coronary CT Angiogram
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 4 Interventional Results available

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

NCT02125279
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcitriol
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Burbank, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

NCT02618759
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

NCT03897088
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
PART 1: Double-blind Placebo-controlled, PART 2: Double-blind Active Treatment Extension
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Encinitas, California • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

NCT01206660
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone Spray 0.25%, placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

NCT00773734
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
20
States / cities
Fresno, California • Los Angeles, California • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 3 Interventional Results available

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

NCT00658788
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jun 26, 2026, 2:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00605059
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I]AV94
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Jun 26, 2026, 2:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jun 26, 2026, 2:47 AM EDT